Navigation Links
Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
Date:7/10/2013

NEW YORK, July 10, 2013 /PRNewswire/ -- Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The study is a randomized, double blind, placebo controlled study enrolling patients at more than twenty clinical sites in the U.S.

"We are excited to have reached the halfway point in the enrollment of our Squalamine Eye Drop study," said Dr. Irach B. Taraporewala, CEO of Ohr. "This milestone sets the stage for the planned interim analysis once the 60 patients complete the nine month treatment protocol, and we expect the data to be available in the second quarter of 2014."

"I am pleased with the continued progress in the trial to evaluate Squalamine Eye Drops for exudative AMD," commented Dr. Jason Slakter, retinal disease specialist at Vitreous-Retina-Macula Consultants of NY, and member of Ohr's scientific advisory board. "The Company's eye drop for treating wet-AMD would potentially offer patients a convenient, self-administered, treatment alternative or adjunct to currently used intravitreal injections directly into the eye. This could be a significant advancement in the future treatment of wet-AMD."

Study OHR-002 is a randomized, double blind, placebo controlled Phase II study to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD. The study will enroll 120 treatment naive wet-AMD patients at more than twenty clinical sites in the U.S., who will be treated with Squalamine Eye Drops or placebo eye drops twice daily for a nine month period. The primary and secondary endpoints include visual acuity parameters, need for rescue intravitreal inj
'/>"/>

SOURCE Ohr Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... D.C. (PRWEB) September 18, 2014 On ... Durbin and Sen. Jim Risch for National Lab Day ... projects from across the national laboratory system. Durbin and ... which aims to increase awareness of the reach of ... technologies and discoveries to address some of our nation's ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... Sept. 18, 2014  U.S. biotech company Kultevat ... exclusive license for technology developed by the Donald ... in plants, including for applications in production of natural ... The technology was developed under the direction of ... and former president of the Danforth Plant Science Center, ...
Breaking Biology Technology:Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2
... my wishes are,coming true," says Kristin Shumpert, who is traveling from ... of Las,Vegas ... and to meet the people who "saved my ... held little interest to the young,woman who suffers from a devastating ... time to use the ladies, room. , ...
... Integrated Knowledge Center Outside the United States. , ... ... Knowledge Center (DKC) today, 17 months after breaking ground last summer. ... the city’s Genome Valley, the center will be a research hub ...
... commercial life sciences sales experience to Cyntellect , ... a privately-held life sciences company leading the development and commercialization ... it has appointed Andre Lubarsky as the Company,s Director of ... sales of Cyntellect,s cell purification and cell health products in ...
Cached Biology Technology:Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 2Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 3Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 4Noninvasive Medical Technologies Helps Make Young Tennessee Woman's Wishes Come True 5DuPont Opens Research & Development Center in India 2DuPont Opens Research & Development Center in India 3Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America 2
(Date:9/18/2014)... AZ, Sept. 18, 2014 -- Arizona turned its newborn ... just a few short months, earning it the first-ever Newborn ... The March of Dimes presented Will Humble, M.P.H., Arizona,s Department ... held here today. Mr. Humble established a policy of full ... to send newborn blood samples to the lab for analysis, ...
(Date:9/18/2014)... will be celebrated tonight at the third annual Golden ... health of premature infants and in paving the way ... work was supported by the National Science Foundation, the ... Commission, will be honored at a ceremony at the ... of Members of Congress will be on hand to ...
(Date:9/18/2014)... September 18, 2014 Elsevier, a world-leading provider ... services, and the Australasian Research Management Society (ARMS), ... scientists at the 5th Scopus Young Researcher of ... earlier today at the National Convention Centre and ... was attended by guests representing Australia,s and New ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... fluctuations in the populations they target, but its not ... journal Nature by scientists at Scripps Institution of Oceanography ... general underlying mechanism. Research led at Scripps with ... two chief scientific advisors to the United Kingdom) demonstrates ...
... worm, University of Maryland researchers have discovered an important ... absorbed and transported into the body. The finding could ... the worlds number one nutritional disorder., With C. elegans, ... Hamza, assistant professor of animal and avian sciences, and ...
... -- Some primates have evolved big brains because their ... advantage that outweighs the demands of extra years of ... Duke University and the University of Zurich have concluded ... key benchmarks in the development of 28 different primate ...
Cached Biology News:Fishing throws targeted species off balance, Scripps study shows 2Fishing throws targeted species off balance, Scripps study shows 3Bloodless worm sheds light on human blood, iron deficiency 2Bloodless worm sheds light on human blood, iron deficiency 3Slowly-developing primates definitely not dim-witted 2Slowly-developing primates definitely not dim-witted 3
Mouse monoclonal antibody to Lats2....
... (eIF4E-binding protein II) is involved in translation ... kidney. PHAS proteins bind to eIF-4E, the ... capped mRNA in vitro and in cells. ... of PHAS/eIF-4E complexes. This allows eIF-4E to ...
MAb to HSV-2, gG-2 HSV-2 Glycoprotein G-2...
... INK4a-ARF locus encodes two unrelated proteins both ... arrests the cell cycle in a p53-dependent ... the rapid degradation of mdm2 proteinrequired for ... accumulation. This interaction is mediated by ...
Biology Products: